| |
|
|
| Year : 2010 | Volume
: 21
| Issue : 4 | Page : 613-620 |
|
| Renal action of C-type natriuretic peptide: Advocating the isolated perfused rat kidney model |
|
|
Peng Hu1, Ling Lu1, Bo Hu1, Yuan Han Qin2
1 Department of Pediatrics, First Affiliated Hospital of Anhui Medical University, Hefei, China
2 Department of Pediatrics, First Affiliated Hospital of Guangxi Medical University, Nanning, China
Click here for correspondence address and email
| Date of Web Publication | 26-Jun-2010 |
|
|
 |
|
 Abstract | | |
C-type natriuretic Peptide (CNP), the third natriuretic peptide (NP) identified, is mainly expressed in the nervous system and endothelial cells. In addition, CNP is believed to be produced locally in tubular cells and glomeruli of normal human kidneys. CNP exerts mainly vasodilatory and anti-mitogenetic effects rather than regulation of body fluid homeostasis via autocrine or paracrine pathway. Many factors, such as shear, pro-inflammatory cytokines and lipopolysaccharide, can regulate the production and excretion of CNP both in vivo and in vitro. However, little information about the renal action of CNP was obtained in the past from the model of isolated perfused rat kidney in which variables could be changed in a controlled manner and systemic influences could be eliminated. However, reviewing the data from the studies that used this model inspires us to conclude that such model can be a useful tool to probe the undiscovered aspects of the renal actions of CNP and should be advocated for future studies on it.
How to cite this article:
Hu P, Lu L, Hu B, Qin YH. Renal action of C-type natriuretic peptide: Advocating the isolated perfused rat kidney model. Saudi J Kidney Dis Transpl 2010;21:613-20 |
How to cite this URL:
Hu P, Lu L, Hu B, Qin YH. Renal action of C-type natriuretic peptide: Advocating the isolated perfused rat kidney model. Saudi J Kidney Dis Transpl [serial online] 2010 [cited 2018 Dec 19];21:613-20. Available from: http://www.sjkdt.org/text.asp?2010/21/4/613/64615 |
| Introduction | |  |
The Natriuretic Peptide (NP) system is a family of hormones with similar molecular structure and physiological function involved in regulation of blood pressure, electrolyte, and volume homeostasis. [1] Moreover, NP system also plays a significant role in inhibiting vascular remodeling after injury. [2] The study of NP began 50 years ago, when electron microscopy revealed the presence of electron-dense "specific atrial granules" in cardiac atrial cells containing atrial natriuretic peptide (ANP) as confirmed by de Bold in the early 80s. [3] From 1998 to 1990, two more members of the NP family, the brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) were identified in porcine brain. [4],[5] Other structurally related peptides include Dendroaspis Natriuretic Peptide (DNP) from the venom of the green mamba, Dendroaspis angusticeps , [6] urodilatin, which is a product of alternative processing of pro-ANP by renal cell, [7] and guanylin and uroguanylin, which were isolated from rat intestine and opossumurine, respectively. [8],[9]
Two CNP fragments with 22 and 53 amino acids are derived from a 103 amino acid CNP precursor; the former sequence being contained within the latter. The 22 amino acid fragment may be regarded as the mature and more biologically active form [Figure 1].
The major sites of CNP expression are the nervous system and endothelial cells. [1],[10] In addition, CNP is believed to be produced locally in tubular cells and glomeruli of normal human kidneys. [11] Unlike the closely related hormone ANF and BNF, CNF does not enter the circulation in significant amounts, and it is regarded as an autocrine or paracrine factor in the tissue and organs in which it is expressed, such as kidneys. [12] CNP elicits mainly vasodilatory effects rather than regulation of body fluid homeostasis. The different physiological effects of these peptides could be attributed to the existence of three different receptors subtypes, natriuretic peptide receptors A, B, and C (NPRA, NPR-B, NPR-C). [13] NPR-A is a guanylate cyclase-coupled receptor activated by ANP, BNP and DNP. NPR-B is also a guanylate cyclase-coupled receptor, which specifically binds CNP and results subsequently in an elevation in intracellular cyclic guanosine monophosphate (cGMP). NPR-C is a truncated protein with an extracellular natriuretic binding domain but only a short 37 amino acid intracellular tail that possesses a G-protein activating sequence. Two different subtypes of NPR-C, of approximately 67 and 77 KD in size have been identified. In general, the main function of the 77 KD NPR-C appears to act as a clearance pathway by binding the NPs and internalizing them, whereas the 67 KD NPR-C is probably in volved in adenylyl cyclase inhibition. [14],[15] These roles are supported by the hypertensive status of NPR-C knockout mice as a result of increased serum concentrations of ANP, BNP and cyclic adenosine monomphsopate (cAMP). [16] The NP system also is inactivated by neutral endopeptidases present within renal tubular cells and vascular cells [Figure 2].
Numerous studies have probed the renal action of CNP in vivo and in vitro. CNP is a potent relaxant of vascular smooth muscle and anti-mitogenetic, but has little effect on salt and water excretion. [17] Lee et al [18] reported that the administration of exogenous CNP (29.3 ng/ kg/min Χ 75min) to seven healthy dogs via intravenous drip could significantly increase serum cGMP [7.8 ± 0.8 pmol/mL (pre-infusion) to 10.1 ± 0.6 pmol/mL (at 60 min of infusion)] and urine flow [0.5 ± 0.1 mL/min (pre-infusion) to 1.3 ± 0.3 mL/min (at 60 min of infusion)], whereas no obvious changes of urinary sodium excretion and glomerular filtration rate (GFR) were observed; these results were consistent with another study in humans. [19] CNP produces vasodilatation of the afferent arteriole via the release of cGMP and nitric oxide (endothelial-derived relaxing factor, EDRF), and vasoconstriction of efferent arteriole selectively, which may attribute to the different distribution of NP receptors in kidney. [20],[21] Furthermore, CNP exerts inhibitory effects on rat mesangial cell proliferation both in vivo and in vitro. [22],[23] Many factors, such as shear, pro-inflammatory cytokines and lipopolysaccharide, can regulate the renal action of CNP. [24],[25],[26] Woodward et al [25] have shown that the production and secretion of CNP in vascular smooth muscle cells (VSMC) was stimulated by transforming growth factor-β(TGF-β), whereas basic fibroblast growth factor (bFGF) played an inhibitory role. In a more recent study, Mendonca et al [27] found that platelet-derived growth factor-BB (PDGF-BB) also induced significant dose-dependent increases in CNP transcript of VSMC in vitro.
Nevertheless, little information about the renal action of CNP is obtained from the model of isolated perfused rat kidney, in which variables can be changed in a controlled manner and systemic influences can be eliminated. Therefore, the use of this model to probe the undiscovered aspects of CNP seems to be appealing.
| Advantages of the Isolated Perfused Rat Kidney Model | | |
The present perfusion techniques for studies of whole organs are derived from those developed in 1950s by Weiss et al. [28] In the past five decades, the isolated perfused rat kidney was considered as a suitable model for the study of many physiological and biochemical aspects of renal function. [29] The advantages of the model are obvious. First, it allows for the direct study of the pre and postglomerular microcirculation with minimal trauma to the vessels or parenchymal tissues. Second, neural and hormonal influences on the renal circulation are eliminated, and perfusion pressure and composition can be controlled. Third, vasoactive agents can be administered to the perfusate or bath. Fourth, tubular and vascular relationships are preserved, and tubuloglomerular feedback system is intact. Fifth, the network basis of the circulation is largely preserved. Finally, pressures, flows, and vascular diameters can be directly measured. [30],[31]
| Data from the Studies on the NP System in Isolated Perfused Rat Kidney | | |
Burton et al [32] measured cGMP release and vascular tone in the isolated kidney of the rat perfused at constant flow with Krebs-Henseleit solution More Details. The effect of ANP (0.01΅M) on the renal release of cGMP and vascular tone was examined. They observed that CNP significantly inhibited the vasoconstrictor response to methoxamine, and produced an immediate and sustained effect on cGMP release, which increased from 0.63 ± 0.36 to 5.80 ± 1.96 pmol/ min during the four to six min period of the ANP infusion. However, both the increase in cGMP release produced by ANF in the isolated perfused kidney and its renal vasodilator activity remained unaffected by treatment with hemoglobin, which acts as an EDRF inhibitor by binding nitric oxide. [33] EDRF synthesis was not involved in either the renal vasodilator activity of ANF or its ability to stimulate cGMP synthesis, which was contrary to the report of Green et al [34] in cultured human glomerular endothelial cells.
Heringlake et al [35] investigated the relationship between arterial blood pressure and renal urodilatin excretion in an isolated perfused rat kidney model. An increase of urodilatin excretion was observed if renal perfusion pressure was raised from 80 to 120 mmHg, accompanied by increased urine flow, urinary sodium, and urinary potassium, whereas the concentration of urodilatin in the perfusate did not change significantly, and serial measurements revealed no direct relation of urodilatin excretion with either urine flow or urinary sodium. This suggests that renal perfusion pressure is a determinant of urodilatin excretion, and urinary and venous effluent concentrations of urodilatin (probably production) are not coupled directly. Furthermore, urodilatin excretion and urinary sodium may dissociate during acute variations of sodium excretion and urine flow in contrast to the in vivo findings of Schmidt et al. [36]
In another study, Fonteles et al [37] compared the biological effects of guanylin and uroguanylin in the isolated perfused rat kidney. They found that both guanylin and uroguanylin increased GER, osmolar clearance, kaliuresis and urinary sodium, with the reduction in fractional sodium reabsorption, but guanylin appeared to be less potent than uroguanylin. Moreover, there was also an experiment designed in the isolated perfused rat kidney to identify possible synergisms between ANP, guanylin and uroguanylin. [38] These experimental results showed that guanylin promoted a reduction in fractional sodium reabsorption, after the pretreatment with ANP. In contrast, ANP blocked uroguanylin-induced increase in urine flow and the reduction in fractional sodium reabsorption. Thus, the synergism between ANP + guanylin and the antagonism between ANP + uroguanylin may be attributed to the existence of different subtypes of receptors mediating the renal actions of guanylins.
After reviewing the data above, we can draw a conclusion that the isolated perfused rat kidney is one of the useful tools to investigate the undiscovered aspects of NP system including physiological effects, pathophysiological indicators, potential therapeutic actions, and interactions with other hormones in the kidney.
| Applied Prospects for the Studies on the Renal Action of CNP in Isolated Perfused Rat Kidney | | |
CNP does not circulate in the blood in appreciable amounts and therefore may act locally in an autocrine or paracrine way. Although little information about the renal action of CNP is obtained from the model of isolated perfused rat kidney, we can presume its applied prospects, depending on the availability of the data from the studies on other NP members in isolated perfused rat kidneys and from the following studies on CNP both in vivo and in vitro.
Involvement of CNP in the Regulation of WaterElectrolyte Homeostasis
In anesthetized rats, [39] conscious sheep, [40] and normal humans, [19] CNP has been shown to be mildly diuretic and natriuretic. However, CNP paradoxically acts as an antinatriuretic substance. This has been suggested by Stingo and colleagues [41] who observed a significant decrease in natriuresis with systemic CNP infusion in the anesthetized dog. The different involvement of CNP in the regulation of waterelectrolyte homeostasis may attribute to the diversities of the experimental conditions in the different species.
Effect of CNP on Renal Hemodynamics
CNP is widely present in endothelium and plays a role in the regulation of vascular tone. Garcha et al[42] demonstrated that CNP relaxes human isolated subcutaneous resistance arteries by local activation of cGMP. On the contrary, when infused in human in vivo, CNP caused no changes on GFR, renal plasma flow (FPR), and renal vascular resistance other than the increased excretion of urinary cGMP. [19] Therefore, the model of isolated perfused rat kidney should be warranted to elucidate the effect of CNP on renal hemodynamics.
Responsibility of CNP to Pressure
A recent article in circulation [43] reports that CNP levels are elevated in the hearts of patients with congestive heart failure, which indicates that locally synthesized CNP in the heart may then compensate for the hypertension induced by fluid volume retention. This date is also supported by the results of Gulberg et al, [44] which showed an increase in urinary CNP excretion in patients with cirrhosis and functional renal failure. To further investigate the origin of increased urinary CNP excretion, CNP plasma concentrations from a systemic artery and renal vein were simultaneously measured in this study. Almost identical concentrations in these two vessels exclude major renal extraction of circulating CNP of systemic origin, which suggests enhanced renal CNP production in cirrhotic patients with hepatorenal syndrome. In addition, more direct evidence from the report of Kim et al [45] indicates that the expression of CNP mRNA was increased in the kidney of obstructive uropathic rats. Different renal perfusion pressure should be held to test the responsibility of CNP in isolated perfused rat kidney.
Influence of CNP on Glomerular Permeability
Nephrotic Syndrome (NS) is characterized by alterations of permselectivity at the glomerular capillary wall, resulting in its inability to restrict the urinary loss of protein. [46] The study of Cataliotti et al [47] illustrated a positive correlation between urinary CNP and albuminuria in patients with NS, and the percent reduction of urinary CNP after low-protein diet was significantly greater than the percent reduction in albuminuria. Therefore, renal release of CNP may alter the glomerular permeability and may be sensitive to manipulations in glomerular function occurring in clinical practice.
Cross-Talking Between CNP and Other NP Members
An inverse relationship between circulating CNP and ANP was observed by Gulberg et al [44] in normal humans. However, intrinsic effects or cross-talking of these peptides, including regulation of ANP release via a short feedback loop, have not yet been clearly defined until a study on perfused atria was conducted by Lee et al [48] who postulated that CNP suppresses the secretion of ANP via the particular NPR-BcGMP pathway. Therefore, a similar study on isolated perfused rat kidney should be undertaken to clarify the cross-talking between CNP and other NP members.
Antagonism between CNP and the ReninAngiotensin-Aldosterone System (RA-AS)
CNP exerts a renoprotective role via inhibition of the RAAS in pathophysiological situations, and has been shown to offer a therapeutic advantage in the treatment of kidney diseases. [15] A recent study has reported that expressions of rennin, angiotensin converting enzyme 1 (ACE1), and CNP mRNA were significantly increased in the rat glomerulus by bilateral ureteral obstruction, which was hypothesized to have compensatory effects offsetting the hypertension induced by fluid retention. [49]
Interaction of CNP with Cytokines
The expression of CNP in vitro is influenced by several cytokines. Dio et al [50] have revealed that the endothelial secretion of CNP is stimulated by TGF-β and tumor necrosis factor-a, which not only causes growth inhibition of VSMC at the G1 phase but also induces the redifferentiation of VSMC and the acceleration of endothelial regeneration. Moreover, a number of studies also demonstrated that CNP expression is enhanced by other cytokines, including interleukin-1, -6, PDGF, and lipopoly saccharide. [23],[27],[51] Conversely, CNP expression is inhibited by oxidized low density lipoprotein, vascular endothelial growth factor, and bFGF. [25],[52],[53] These results should be confirmed by the studies on isolated perfused rat kidney.
| Conclusions | | |
Little information about the renal action of CNP is obtained from the model of isolated perfused rat kidney. After comprehending the advantages of the isolated perfused rat kidney model, reviewing the data from the studies on other NP members in isolated perfused rat kidney, and hypothesizing the applied prospects for the studies on the renal action of CNP in isolated perfused rat kidney, we can conclude that the isolated perfused rat kidney is one of the useful tools to investigate the renal action of CNP and should be advocated for future research on it.
| Acknowledgement | | |
The authors would like to gratefully acknowledge the most helpful comments on this review received from Professor Shi Jun Zhang, Department of physiology, Gunagxi Medical University, Nanning.
| References | | |
| 1. | Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.  |
| 2. | Franco V, Chen YF, Oparil S, et al. Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling. Hypertension 2004;44:746-50. |
| 3. | De Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981;28:89-94. |
| 4. | Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81. |
| 5. | Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990;168:863-70. |
| 6. | Schweitz H, Vigne P, Moinier D, Frelin C, Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem 1992;267:13928-32. |
| 7. | Schulz-Knappe P, Forssmann K, Herbst F, Hock D, Pipkorn R, Forssmann WG. Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988;66:752-9. |
| 8. | Currie MG, Fok KF, Kato J, Hamra FK, Duffin KL, Smith CE. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci USA 1992;89:947-51. |
| 9. | Hamra FK, Forte LR, Eber SL, et al. Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci USA 1993;90:10464-8. |
| 10. | Baxter GF. The natriuretic peptides. Basic Res Cardiol 2004;99:71-5. |
| 11. | Cataliotti A, Giordano M, De Pascale E, et al. CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome. Am J Physiol Renal Physiol 2002;283:F464-72. |
| 12. | Lohe A, Yeh I, Hyver T, Pratt R, Jamison R. Natriuretic peptide B receptor and C-type natriuretic peptide in the rat kidney. J Am Soc Nephrol 1995;6:1552-8. |
| 13. | Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J Hypertens 1992;10:1111-4. |
| 14. | Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006;27:47-72. |
| 15. | Woodard GE, Rosado JA. Recent advances in natriuretic peptide research. J Cell Mol Med 2007;11:1263-71. |
| 16. | Rose RA, Giles WR. Natriuretic peptide C receptor signaling in the heart and vasculature. J Physiol 2008;586:353-66. |
| 17. | Ahluwalia A, MacAllister RJ, Hobbs AJ. Vascular actions of natriuretic peptides. Cyclic GMPdependent and -independent mechanisms. Basic Res Cardiol 2004;99:83-9. |
| 18. | Lee C. YW, Boerrigter G, Harty GJ, Burnett JC. Cardiorenal actions of a novel chimeric natriuretic peptide, CD-NP, as compared to C-type natriuretic peptide, in the normal dog. BMC Pharmacology 2007;7:37. |
| 19. | Pham I, Sediame S, Maistre G, et al. Renal and vascular effects of C-type and atrial natriuretic peptides in humans. Am J Physiol 1997;273: R1457-64. |
| 20. | Rivero-Vilches FJ, de Frutos S, Saura M, Rodriguez-Puyol D, Rodriguez-Puyol M. Differential relaxing responses to particulate or soluble guanylyl cyclase activation on endothelial cells: a mechanism dependent on PKG-I alpha activation by NO/cGMP. Am J Physiol Cell Physiol 2003;285:C891-8. |
| 21. | Ritter D, Dean AD, Gluck SL, Greenwald JE. Natriuretic peptide receptors A and B have differrent cellular distributions in rat kidney. Kidney Int 1995;48:5758-66. |
| 22. | Canaan-Kiihl S, Ostendorf T, Zander K, Koch KM, Floege J. C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo. Kidney Int 1998;53: 1143-51. |
| 23. | Segawa K, Minami K, Jimi N, Nakashima Y, Shigematsu A. C-type natriuretic peptide inhibits rat mesangial cell proliferation by a phosphorrylation-dependent mechanism. Naunyn Schmiedebergs Arch Pharmacol 1998;357:70-6. |
| 24. | Chun TH, Itoh H, Ogawa Y, et al. Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension 1997;29: 1296-302. |
| 25. | Woodard GE, Rosado JA, Brown J. Expression and control of C-type natriuretic peptide in rat vascular smooth muscle cells. Am J Physiol Regul Integr Comp Physiol 2002;282:R156-65. |
| 26. | Qian JY, Haruno A, Asada Y, et al. Local expression of C-type natriuretic peptide suppresses inflammation, eliminates shear stressinduced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arteries. Circ Res 2002;91:1063-9. |
| 27. | Mendonga MC, Doi SQ, Glerum S, Sellitti DF. Increase of C-type natriuretic peptide expression by serum and platelet-derived growth factorBB in human aortic smooth muscle cells is dependent on protein kinase C activation. Endocrinology 2006;147:4169-78. |
| 28. | Weiss C, Passow H, Rothstein A. Autoregulation of flow in isolated rat kidney in the absence of red cells. Am J Physiol 1959;196:1115-8. |
| 29. | Taft DR. The isolated perfused rat kidney model: a useful tool for drug discovery and development. Curr Drug Discov Technol 2004; 1:97-111. |
| 30. | Roman RJ, Carmines PK, Loutzenhiser R, Conger JD. Direct studies on the control of the renal microcirculation. J Am Soc Nephrol 1991; 2:136-49. |
| 31. | Ross BD. The isolated perfused rat kidney. Clin Sci Mol Med Suppl 1978;55:513-21. |
| 32. | Burton GA, MacNeil S, de Jonge A, Haylor J. Cyclic GMP release and vasodilatation induced by EDRF and atrial natriuretic factor in the isolated perfused kidney of the rat. Br J Pharmacol 1990;99:364-8. |
| 33. | Gibson WH, Roughton FJ. The kinetics and equilibria of the reactions of nitric oxide with sheep haemoglobin. J Physiol 1957;136:507-24. |
| 34. | Green DF, Duruibe VA, Blyden G, Laskey RE, Bourgoignie JJ. Uptake of atrial natriuretic peptide and production of cGMP in cultured human glomerular endothelial cells. J Am Soc Nephrol 1994;5:1091-8. |
| 35. | Heringlake M, Wagner K, Schumacher J, Pagel H. Urinary excretion of urodilatin is increased during pressure natriuresis in the isolated perfused rat kidney. Am J Physiol 1999;277: F347-51. |
| 36. | Schmidt W, Bub A, Meyer M, Weiss T, Schneider G, Maassen N, Forssmann WG. Is urodilatin the missing link in exercise-dependent renal sodium retention? J Appl Physiol 1998;84:123-8. |
| 37. | Fonteles MC, Greenberg RN, Monteiro HS, Currie MG, Forte LR. Natriuretic and kaliuretic activities of guanylin and uroguanylin in the isolated perfused rat kidney. Am J Physiol 1998;275:F191-7. |
| 38. | Santos-Neto MS, Carvalho AF, Forte LR, Fonteles MC. Relationship between the actions of atrial natriuretic peptide (ANP), guanylin and uroguanylin on the isolated kidney. Braz J Med Biol Res 1999;32:1015-9. |
| 39. | Shin SJ, Wen JD, Lee YJ, Chen IH, Tsai JH. Increased C-type natriuretic peptide mRNA expression in the kidney of diabetic rats. J Endocrinol 1998;158:35-42. |
| 40. | Charles CJ, Espiner EA, Richards AM, Nicholls MG, Yandle TG. Comparative bioactivity of atrial, brain, and C-type natriuretic peptides in conscious sheep. Am J Physiol 1996;270: R1324-31. |
| 41. | Stingo AJ, Clavell AL, Aarhus LL, Burnett JC Jr. Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol 1992;262: H308-12. |
| 42. | Garcha RS, Hughes AD. CNP, but not ANP or BNP, relax human isolated subcutaneous resistance arteries by an action involving cyclic GMP and BKCa channels. J Renin Angiotensin Aldosterone Syst 2002;7:87-91. |
| 43. | Kalra PR, Clague JR, Bolger AP, et al. Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 2003;107: 571-3. |
| 44. | Giilberg V, M, ller S, Henriksen JH, Gerbes AL. Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure. Gut 2000;47:852-7. |
| 45. | Kim SW, Li Y, Kim S, Oh YW, Lee JU. Local renal and vascular natriuretic peptide system in obstructive uropathic rats. Urol Res 2002; 30:97-101. |
| 46. | Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med 1998;338:1202-1211. |
| 47. | Cataliotti A, Giordano M, De Pascale E, et al. CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome. Am J Physiol Renal Physiol 2002;283: F464-72. |
| 48. | Lee SJ, Kim SZ, Cui X, et al. C-type natriuretic peptide inhibits ANP secretion and atrial dynamics in perfused atria: NPR-B-cGMP signaling. Am J Physiol Heart Circ Physiol 2000;278:H208-21. |
| 49. | Bae EH, Kim SW. Upregulation of renninangiotensin, endothelin and C-type natriuretic peptide in rat glomerulus with bilateral ureteral obstruction. Korean J Physiol Pharmacol 2006; 10:343-7. |
| 50. | Doi K, Ikeda T, Itoh H, et al. C-type natriuretic peptide induces redifferentiation of vascular smooth muscle cells with accelerated reendothelialization. Arterioscler Thromb Vasc Biol 2001;21:930-6. |
| 51. | Suga S, Itoh H, Komatsu Y, et al. Cytokineinduced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells-evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology 1993; 133:3038-41. |
| 52. | Kohno M, Yokokawa K, Yasunari K, et al. Effect of natriuretic peptide family on the oxidized LDL-induced migration of human coronary artery smooth muscle cells. Circ Res 1997; 81:585-90. |
| 53. | Doi K, Itoh H, Komatsu Y, et al. Vascular endothelial growth factor suppresses C-type natriuretic peptide secretion. Hypertension 1996;27:811-5. |
Correspondence Address:
Peng Hu
Department of Pediatrics, First Affiliated Hospital of Anhui, Medical University, No.218 Jixi Road, Hefei, 230022
China
  | Check |
PMID: 20587862 
[Figure 1], [Figure 2] |
|
| This article has been cited by | | 1 |
Regulation of C-type natriuretic peptides and natriuretic peptide receptor-B expression in diabetic rats renal treated by Tongluo Recipe |
|
| Qu, W. and Jiang, Z.-S. and Zhang, C.-Y. and Zou, J.-J. and Sun, L.-L. and Shi, Y.-Q. and Liu, Z.-M. | | Chinese Journal of Integrative Medicine. 2013; 19(7): 524-531 | | [Pubmed] | | | 2 |
Anti-neutral endopeptidase, natriuretic peptides disarrangement, and proteinuria onset in membranous nephropathy |
|
| Hu, P. and Xuan, Q. and Hu, B. and Lu, L. and Qin, Y.H. | | Molecular Biology Reports. 2013; 40(4): 2963-2967 | | [Pubmed] | | | 3 |
Overexpressed C-type natriuretic peptide serves as an early compensatory response to counteract extracellular matrix remodeling in unilateral ureteral obstruction rats |
|
| Hu, P. and Wang, J. and Zhao, X.Q. and Hu, B. and Lu, L. and Qin, Y.H. | | Molecular Biology Reports. 2013; 40(2): 1429-1441 | | [Pubmed] | | | 4 |
New method for isolation of both kidneys for studies of vascular reactivity in rats |
|
| Vargas-Tendero, P. and RodrÃguez-Gómez, I. and Wangensteen, R. and Arcas, R. and Quintana, M. and Vargas, F. | | Experimental Biology and Medicine. 2012; 237(12): 1457-1461 | | [Pubmed] | | | 5 |
Increased urinary C-type natriuretic peptide excretion may be an early marker of renal tubulointerstitial fibrosis |
|
| Hu, P. and Wang, J. and Hu, B. and Lu, L. and Xuan, Q. and Qin, Y.H. | | Peptides. 2012; 37(1): 98-105 | | [Pubmed] | | | 6 |
Impact of oxLDL and LPS on C-type natriuretic peptide system is different between THP-1 cells and human peripheral blood monocytic cells |
|
| Bruckmeier, M. and Kuehnl, A. and Culmes, M. and Pelisek, J. and Eckstein, H.-H. | | Cellular Physiology and Biochemistry. 2012; 30(1): 199-209 | | [Pubmed] | |
|
|
|
|
|
|
|
|
|
|
|
|
| Article Access Statistics | | | Viewed | 2948 | | | Printed | 110 | | | Emailed | 0 | | | PDF Downloaded | 742 | | | Comments | [Add] | | | Cited by others | 6 | | |
|
|
